Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae

Antimicrob Agents Chemother. 2002 Aug;46(8):2712-5. doi: 10.1128/AAC.46.8.2712-2715.2002.

Abstract

We analyzed the frequencies of selection, the order of acquisition, and the mutations selected on moxifloxacin in two wild-type pneumococcal strains, R6 and 5714. The first selection step showed either a single GyrA mutation or no mutation in any of the quinolone resistance-determining regions. Second-step mutants selected had either a second mutation in ParC or in ParE. Moxifloxacin could belong to these fluoroquinolones, which preferentially target GyrA though probably acting equally through both gyrase and topoisomerase IV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Anti-Infective Agents / pharmacology*
  • Aza Compounds*
  • DNA Gyrase / genetics
  • DNA Topoisomerase IV / genetics
  • DNA Topoisomerases, Type I / genetics*
  • Drug Resistance, Microbial
  • Fluoroquinolones*
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Mutation / genetics*
  • Quinolines*
  • Streptococcus pneumoniae / drug effects*

Substances

  • Anti-Infective Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • DNA Topoisomerase IV
  • DNA Topoisomerases, Type I
  • DNA Gyrase
  • Moxifloxacin